Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have significantly improved response rates compared with conventional chemotherapy in patients with EGFR mutations in non-small cell lung cancer (NSCLC) [1-4]. Here, EGFR is linked to non-small cell lung carcinoma.